Osiris Therapeutics Inc (NASDAQ:OSIR) to Host Q4 Conference Call February 24

Ft Lauderdale, Florida 2/13/2010 12:15 AM GMT (TransWorldNews)

Osiris Therapeutics, Inc. (NASDAQ:OSIR) has announced that it has scheduled a conference call for Wednesday, February 24, 2010.  The call is being held to review the financial results for its fourth quarter and full year ended December 31, 2009.  Hosting the call will be Osiris’ President and Chief Executive Officer C. Randal Mills, PH.D., and Chief Financial Officer, Phip Jacoby, Jr.  The call is scheduled to begin at 9:00 am ET.


 


Simply Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.


Sign Up for our Free Stock Newsletter


 


Individuals may access the call via webcast on the company’s Investor Relations page, http://investor.osiris.com/.  Those preferring to listen over the phone may dial 877.303.6133, or 970.315.0493 for callers outside of the United States.  A replay of the call will also be available until March 10, 2010 by dialing 800.642.1687, or 706.645.9291.  The replay pass code is 56969647.  The webcast will also remain on the site for instant replay following the conclusion of the call.


 


Osiris Therapeutics, Inc. (Osiris) is a stem cell therapeutic company, focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The Company’s principal biologic drug candidate, Prochymal, is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease (GvHD), Crohn's disease and for the repair of gastrointestinal injury resulting from radiation exposure, and is the only stem cell therapeutic granted both Orphan Drug and Fast Track status by the United States Food and Drug Administration (FDA). Its pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen for osteoarthritis in the knee. In August 2009, the Company announced the creation of a new Biosurgery Division focused on developing and marketing high-end biological products for use in surgical procedures.


 


Sign up for the free Simply Best Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.


 


Follow Simply Best Penny Stocks on Twitter: http://www.Twitter.com/simplybestps


 


About Us


 


Simply Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.


 


Please click here to read the full disclaimer.


 

info@simplybestpennystocks.com
www.simplybestpennystocks.com

 

News Alerts

Receive alerts for Simply Best Penny Stocks to your inbox. Sign up for News Alerts

Empty Image

TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.

Empty Image